Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1888
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis ; day:26 ; month:10 ; year:2021 ; pages:1-11
American journal of clinical dermatology ; (26.10.2021), 1-11
- Urheber
-
Silverberg, Jonathan I.
Simpson, Eric L.
Armstrong, April W.
Bruin-Weller, Marjolein S. de
Irvine, Alan D.
Reich, Kristian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40257-021-00639-y
- URN
-
urn:nbn:de:101:1-2022011519331508006578
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Silverberg, Jonathan I.
- Simpson, Eric L.
- Armstrong, April W.
- Bruin-Weller, Marjolein S. de
- Irvine, Alan D.
- Reich, Kristian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study